CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS

2021

MEDICATION GUIDELINES FOR SOLID ORGAN TRANSPLANTS

Revised May 2021v2 ? Tacrolimus target level update ? Hep B section update ? Management guidelines section

AMB.03.007 Rev11 Eff Date: 13-May-21

_______________________________________________________________________

Table of Contents (Click links to drug sections)

1. Introduction 2. Anti-lymphocyte polyclonal antibody (ATG) 3. Azathioprine 4. Basiliximab 5. Cyclosporine 6. Erythropoiesis-Stimulating Agents (Darbepoetin/Erythropoietin)

7. Filgrastim (G-CSF)

8. Hepatitis B Antiviral Agents (Entecavir, Tenofovir, Lamivudine) 9. Letermovir 10.Mycophenolic Acids: Mycophenolate Mofetil and Mycophenolate

Sodium 11. Prednisone 12. Sirolimus 13. Tacrolimus 14. Valganciclovir 15. Management Guidelines (BK virus; dental prophylaxis; Herpes

simplex virus; immunization; Pneumocystis jiroveci (PJP); posttransplant diarrhea; post-transplant neutropenia) 16. Appendices (sirolimus; ESA and filgrastim request forms)

Page 3 5

10 13 18 30 35 39 45 48

57 62 76 88 102

115

Table of Contents ________________________________________________________________________

Introduction

Patients who undergo solid organ transplant require lifelong immunosuppression to prevent organ rejection. In organ transplantation, the ideal form of immunosuppression is to induce donor specific tolerance without impairing the host defences or increasing the susceptibility to infection from all types of organisms.

The most common immunosuppressants prescribed for solid organ transplant recipients are:

? Calcineurin Inhibitors: Cyclosporine Tacrolimus

? Mycophenolic Acids: Mycophenolate Mofetil Mycophenolate Sodium

? Azathioprine ? Sirolimus ? Prednisone ? Basiliximab ? Anti-thymocyte Globulin

Each of these drugs has its own adverse effect and toxicity profile that may result in serious morbidity or mortality. Careful management of these complications by the patient and the transplant team is critical to transplant success.

BC Transplant funds the following outpatient immunosuppressants for solid organ and pancreatic islet cell transplant recipients who have BC Medical Services Plan coverage and are registered with BC Transplant, when the guidelines are followed:

Outpatient Immunosuppression: ? Calcineurin Inhibitors: Cyclosporine Tacrolimus IMMEDIATE Release Tacrolimus EXTENDED Release ? Mycophenolic Acids: Mycophenolate Mofetil Mycophenolate Sodium ? Azathioprine ? Sirolimus ? Prednisone

Clinical Guidelines for Transplant Medications

Page 3

Table of Contents ________________________________________________________________________

Inpatient Immunosuppression BC Transplant funds the inpatient immunosuppressant basiliximab and entanercept for pancreatic islet cell transplant when the guidelines are followed.

Special Outpatient Medications Required to Maintain Transplant In addition to immunosuppressants, solid organ transplant recipients often require other outpatient medications which are needed to maintain the integrity of the transplant and are very important in a patients' medication regimen. BC Transplant covers the cost of the following medications if the guidelines are met:

Erythropoiesis - Stimulating Agents: ? Erythropoietin ? Darbepoetin

Anti-Viral Agents: ? Valganciclovir ? Lamivudine ? Adefovir ? Tenofovir ? Entecavir ? Leflunomide

Clinical Guidelines for Transplant Medications

Page 4

Table of Contents

________________________________________________________________________

Anti-lymphocyte polyclonal antibody (ATG)

INTRODUCTION

Anti-thymocyte globulin (ATG) is a pasteurized solution of rabbit-derived polyclonal IgG antibodies directed against human T cells, produced by immunization of rabbits with human lymphocytes. This monograph will focus on its use in solid organ transplants. ATG is funded by the inpatient pharmacy drug budget and not covered by BC Transplant.

MECHANISM OF ACTION

ATG is potent immunosuppressant and immunomodulator whose mechanisms of action are not fully understood.

The mixture of antibodies recognize key receptors on T-cells, resulting in complement-dependent T-cell lysis and opsonisation of T-cells with subsequent phagocytosis by macrophages. Thymopoiesis is also impaired, resulting in a decrease in the number of newly formed T-cells. This causes a substantial drop in the number of circulating T-cells, hence reducing the risk of organ rejection.

The usual magnitude is a greater than 90% reduction in the number of circulating T-cells. The duration of lymphopenia lasts around 3 months for most patients, though some have had sustained lymphopenia for over 1 year post-ATG.

ATG has shown benefits for patients at high risk of delayed graft function (DGF), potentially due to reducing ischemia-reperfusion injury by inflammatory mediators produced from T-lymphocytes.

PHARMACOKINETICS

Absorption / Onset: T-cell depletion is usually noted within 1 day of the first ATG dose.

Distribution: The volume of distribution of ATG is approximately 2 times plasma volume. Distribution into breast milk is unknown, though other immunoglobulins do enter breast milk.

Metabolism: Likely removed via opsonisation by the reticuloendothelial system if bound to T-cells, or via human antibody production.

Elimination: Plasma half-life is variable (1.5 to 30 days5, usually 2 to 3 days). ATG remains active for days to weeks post-treatment. The primary route of elimination is via cellular uptake with subsequent proteolytic degradation. Hence, no dosage adjustment is required in renal or hepatic impairment.

Clinical Guidelines for Transplant Medications

Page 5

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download